痴呆命名新框架
美国「应对阿尔茨海默病国家计划」研究、照护与服务咨询委员会授权成立痴呆命名倡议,通过文献综述和焦点小组制定新框架,将临床综合征表现与可能潜在病理生理分开,以标准化研究、临床和公共卫生领域的语言使用。
要点
- 新框架将临床损害域(认知、行为、运动等)按无至重度分级。
- 生物标志物信息用于描述潜在疾病过程并可能给出疾病标签。
- 框架需更广泛测试和完善以改善沟通信息的使用。
核心结论
- 痴呆命名倡议建立了一个框架,用于指导关于老年人认知损害的沟通。
研究设计与样本
- 痴呆命名倡议组织临床医生、研究人员和公众(包括痴呆患者及家庭照护者)三个利益相关工作组,并完成叙述性文献综述(PubMed、CINAHL、PsycInfo、Scopus,2000年1月1日至2020年7月31日)及按种族和族裔分组的焦点小组。
主要发现
- 框架将患者经历的临床综合征表现与可能的潜在病理生理清晰分开。
- 临床损害域(认知、行为、运动和其他神经特征)按无至重度分级。
- 生物标志物信息描述潜在疾病过程、解释综合征并识别可能的疾病标签:阿尔茨海默病、额颞叶变性、路易体痴呆或血管性认知损害痴呆。
临床怎么用
- 作者认为更广泛测试和完善该框架将改善用于沟通认知损害的信息及其在临床、研究和公共环境中的使用方式。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Nomenclature in the field of neurodegenerative diseases presents a challenging problem. Inconsistent use of terms such as Alzheimer disease and dementia has compromised progress in clinical care, research, and development of therapeutics. Dementia-associated stigma further contributes to inconsistent and imprecise language. The result is a lack of clarity that produces confusion with patients and the general public and presents communication challenges among researchers. Therefore, the Advisory Council on Research, Care, and Services of the National Plan to Address Alzheimer's Disease authorized a committee to make recommendations for improvement. OBJECTIVE: To establish a systematic neurodegenerative disease framework for information collection and communication to standardize language usage for research, clinical, and public health purposes. EVIDENCE REVIEW: The Dementia Nomenclature Initiative organized into 3 major stakeholder working groups: clinicians, researchers, and the public (including individuals living with dementia and family caregivers). To inform the work, the initiative completed a narrative literature review of dementia nomenclature evolution over the last century across the PubMed, CINAHL, PsycInfo, and Scopus databases (January 1, 2000, through July 31, 2020). Initiative working groups used the results as a foundation for understanding current challenges with dementia nomenclature and implications for research, clinical practice, and public understanding. The initiative obtained additional input via focus groups with individuals living with dementia and caregivers, with separate groups for race and ethnicity (American Indian or Alaska Native, Asian or Pacific Islander, Black or African American, Hispanic or Latino, and White) as an initial assessment of the meaning of dementia-related terms to these groups. FINDINGS: From working group deliberations, the literature review, and focus group input, the initiative developed a framework clearly separating the clinical syndromic presentation experienced by affected individuals from possible underlying pathophysiologies. In the framework, domains of clinical impairment, such as cognitive, behavioral, motor, and other neurologic features, are graded by level of impairment between none and severe. Next, biomarker information describes underlying disease processes, explains the syndrome, and identifies possible disease labels: Alzheimer disease, frontotemporal degeneration, dementia with Lewy bodies, or vascular cognitive impairment dementia. CONCLUSIONS AND RELEVANCE: The Dementia Nomenclature Initiative established a framework to guide communication about cognitive impairment among older adults. Wider testing and refinement of the framework will subsequently improve the information used in communicating about cognitive impairment and the way in which the information is used in clinical, research, and public settings.
引用
- Petersen RC, Weintraub S, Sabbagh M, et al. A New Framework for Dementia Nomenclature. JAMA Neurol. 2023. PMID: 37843871. doi:10.1001/jamaneurol.2023.3664
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。